[Skip to Content]
[Skip to Content Landing]
May 27, 1998

Lipid-Lowering Therapy in Low-Risk Patients

Author Affiliations

From the University of Rochester School of Medicine, Rochester, NY.

JAMA. 1998;279(20):1659-1661. doi:10.1001/jama.279.20.1659

In this issue of THE JOURNAL, Downs et al1 present the primary results of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). The study is yet another randomized, placebo-controlled, clinical trial of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, in this case lovastatin, as a means to prevent atherosclerotic coronary artery disease. Although readers might wonder what such a trial might add to understanding the role of lipid-lowering therapy in general, or of the use of the so-called statins in particular, this trial is of singular importance and timeliness to guide the use of these agents in the controversial area of the primary prevention of cardiovascular disease.

First Page Preview View Large
First page PDF preview
First page PDF preview